Clinical trial Recruiting at 1 site Observational Ages 18 to 85

Controlling blood uric acid after pancreatic cancer surgery to improve survival

Official title: Whether Controlling Serum Uric Acid (SUA) Can Benefit Postoperative Survival in Patients With Pancreatic Cancer

Run by Hepatopancreatobiliary Surgery Institute of Gansu Province · NCT07091526 · Data updated 2026-11-12

This analysis will see if changes in blood uric acid after pancreatic cancer surgery relate to survival for people who had their tumor removed.

More Uric Acid trials

Quick facts

Study typeObservational
Ages18 Years to 85 Years
SexAll
Enrollment168 (estimated)
SponsorHepatopancreatobiliary Surgery Institute of Gansu Province
Academic / other
Locations1 site (Lanzhou, Gansu)
StatusRecruiting
StartedJuly 29, 2025
Main results expectedDecember 29, 2026
Study endsDecember 29, 2026
Registry record updatedDecember 19, 2025
Trial IDNCT07091526 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults with pathologically confirmed primary pancreatic cancer who underwent radical resection (pancreaticoduodenectomy or distal pancreatectomy), have available pre- and postoperative uric acid measurements, and survived at least six weeks after surgery are the intended population.

Probably not a fit

Patients with preexisting gout, chronic kidney disease, use of long-term urate-lowering drugs, recent dialysis or plasma exchange, certain metabolic or hematologic disorders, nonpancreatic primary tumors, pregnant or postpartum women, or those lacking follow-up data are unlikely to benefit from these findings.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a retrospective observational analysis of patients with pathologically confirmed primary pancreatic cancer who underwent radical resection (pancreaticoduodenectomy or distal pancreatectomy) at a single center in Lanzhou, Gansu. Investigators will extract preoperative and postoperative serum uric acid (SUA) measurements from medical records and correlate changes in SUA with overall survival and postoperative outcomes, using available clinical data to adjust for confounders. Patients with conditions or treatments that substantially affect uric acid (for example gout, chronic kidney disease, or long-term urate-lowering therapy) are excluded to reduce bias. The study aims to determine whether perioperative changes in SUA can serve as a prognostic marker after pancreatic cancer resection.

Why it matters

Potential benefit: If successful, tracking postoperative uric acid changes could help identify patients at higher risk of poor survival and guide closer follow-up or targeted interventions.

How similar studies have gone: Some observational work has linked higher serum uric acid to worse outcomes in hepatobiliary cancers, but using postoperative change in SUA as a prognostic marker specifically for pancreatic cancer is novel and not yet established.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Patients with pathologically confirmed pancreatic cancer (primary)
* Patients who underwent Radical resection of pancreatic cancer(Pancreaticoduodenectomy or Distal pancreatectomy)
* The postoperative survival time was at least 6 weeks

Exclusion Criteria:

* No surgery was performed, or only palliative surgery/ biopsy was performed
* Patients who underwent emergency hemodialysis or plasma exchange after surgery
* History of gout or long-term urate-lowering therapy, such as allopurinol
* Patients are missing follow-up data
* Hydrochlorothiazide and furosemide were used
* Chronic kidney disease
* Oncolytic syndrome
* Hemolytic anemia
* Lead poisoning
* Hyperparathyroidism
* Hypothyroidism
* A tyrosinase inhibitor was used
* Patients with nonpancreatic primary tumors
* Pregnant or postpartum women.

Where it's running

  • Hepatopancreatobiliary Surgery Institute of Gansu Province
    Lanzhou, Gansu, China
    Recruiting

Study contacts

  • Principal investigator: Wenbo Meng, M.D. Ph. D. — Hepatopancreatobiliary Surgery Institute of Gansu Province
  • Study coordinator: Wenbo Meng, M.D. Ph. D.
  • Email: mengwb@163.com
  • Phone: 13919177177

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.